The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...
El 21 de octubre de 2007 es un día que muchos de nosotros en San Diego nunca olvidaremos. Estaba en Ocean Beach disfrutando ...
Currently, many gene therapies using viral-free vectors rely on ex vivo editing. This involves removing a patient’s cells, editing them in a lab, and reintroducing them into the body. While effective, ...
That is why the company is also working on gene therapy and ex vivo gene-edited cell therapy. “If you’re working in gene editing, you can also work in gene therapy, because you already know a ...
The companies all use modified versions of the same lentiviral vectors used in ex vivo CAR-T therapy ... In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson ...
An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...
Tuberculosis (TB), a major global health issue, affects millions worldwide with latent and active infections. This airborne ...
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
A 6.5-month-old boy with the rare inherited urea cycle disorder ornithine transcarbamylase (OTC) deficiency has responded positively in a targeted in vivo gene editing trial, in which a correct copy ...
The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback